

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Maxidex 0.1% Ophthalmic Suspension (DIN 00042560) manufactured by Novartis Pharmaceuticals Canada Inc., Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865) manufactured by Pharma Stulln Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **November 1, 2022**.

As of **November 1, 2022**, and until further notice, all claims for Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)*. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Due to the unavailability of Isopto Atropine 1% Ophthalmic Solution (DIN 00035017) manufactured by Alcon Canada Inc., Atropine Sulfate 1% Ophthalmic Solution (Minims) (DIN 02148358) manufactured by Bausch and Lomb Canada Inc., will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was previously added to the Critical Supply Product List on **November 1, 2022**.

As of **November 1, 2022**, and until further notice, all claims for Atropine Sulfate 1% Ophthalmic Solution (Minims) (DIN 02148358) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)*. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Due to the unavailability of Sandoz Fluorometholone 0.1% Ophthalmic Suspension (DIN 00432814) manufactured by Sandoz Canada Inc., FML Liquifilm 0.1% Ophthalmic Suspension (DIN 00247855) manufactured by Allergan Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was previously added to the Critical Supply Product List on **November 8, 2022**.

As of **November 8, 2022**, and until further notice, all claims for FML Liquifilm 0.1% Ophthalmic Suspension (DIN 00247855) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)*. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Due to the unavailability of Teva-Codeine 15 mg Tablet (DIN 00593435) and Teva-Codeine 30 mg Tablet (DIN 00593451) manufactured by Teva Canada Limited, Codeine Phosphate 5 mg/ml Oral Syrup (DIN 00050024) manufactured by Atlas Laboratories Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **November 8, 2022**.

As of **November 8, 2022**, and until further notice, all claims for Codeine Phosphate 5 mg/ml Oral Syrup (DIN 00050024) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)*. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

continued next page

continued from previous page

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Morphine SR 200 mg Sustained-Release Tablet (DIN 02302802) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **December 5, 2022**. The following grouping was removed from the Critical Supply Product List on **November 4, 2022**.

MORPHINE SULFATE

200 MG ORAL SUSTAINED-RELEASE TABLET

00002478897	SANDOZ MORPHINE SR	SDZ	\$ 2.7718
00002302802	TEVA-MORPHINE SR	TEV	\$ 2.7718
00002014327	MS CONTIN	PUR	\$ 5.8845

Alberta Blue Cross has been advised by Auro Pharma, Jamp Pharma Corporation and Pharmascience Inc. that the shortage for Auro-Losartan 50 mg Tablet (DIN 02403331), Jamp-Losartan 50 mg Tablet (DIN 02398842) and pms-Losartan 50 mg Tablet (DIN 02309769) respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **December 15, 2022**. The following grouping was removed from the Critical Supply Product List on **November 15, 2022**.

LOSARTAN POTASSIUM

50 MG TABLET

00002353504	APO-LOSARTAN	APX	\$ 0.1616
00002403331	AURO-LOSARTAN	AUR	\$ 0.1616
00002398842	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388804	LOSARTAN	SIV	\$ 0.1616
00002388871	LOSARTAN	SNS	\$ 0.1616
00002405741	MINT-LOSARTAN	MPI	\$ 0.1616
00002309769	PMS-LOSARTAN	PMS	\$ 0.1616
00002313340	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424975	SEPTA-LOSARTAN	SEP	\$ 0.1616
00002357968	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182874	COZAAR	ORC	\$ 1.4504

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
 403-294-4041 (Calgary and area)
 1-800-361-9632 (toll free)
 FAX 780-498-8406 (Edmonton and area)
 FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

